JP3940751B2 - Method for distinguishing genotype of hepatitis C virus - Google Patents

Description

  The present invention relates to a novel oligonucleotide, a hepatitis C virus genotype discrimination primer comprising the same, and a hepatitis C virus genotype discrimination method using the same.

  The gene sequence of hepatitis C virus (hereinafter sometimes referred to as “HCV”) around the world has been determined (for example, Japanese translations of PCT publication No. 5-500155 and Japanese Patent Laid-Open No. 5-301877). HCV was found to exist. Conventionally, virus type classification has been widely used for molecular epidemiological research studies such as estimation of the source of infection and its geographical distribution. However, regarding HCV, clinically effective interferon treatment of chronic hepatitis C patients This proved to be useful for prediction, and HCV type classification was absolutely necessary for treatment.

  Conventionally, when classifying viruses, serotypes utilizing the difference in antigenicity of viruses have been used. However, it has been found that accurate typing cannot be performed with serotypes. On the other hand, the proteins constituting the virus are encoded by genes. And it evolves by mutation of the gene. Therefore, when comparing between viruses, it is more essential to compare differences between viral genes than to compare the serotypes described above. That is, it is more essential and accurate to classify HCV based on genotype (genotype).

Traditionally, the classification of HCV genotypes varies from investigator to investigator. Therefore, even if a researcher announces a research on a genotype, other researchers cannot clearly know which classification the genotype is using, and other research It was a problem because the results of those who were not able to use them efficiently could not be used. Therefore, in order to internationally unify the classification of HCV genotypes, researchers from various countries jointly proposed a unified genotype classification method (Hepatology, 19: 1321-1334, 1994, Correspondence, “A Proposed System for the Nomenclature of Hepatitis C Viral Genotypes”, hereinafter, this classification method may be referred to as “international unified classification method” for convenience). This international unified classification method classifies HCV into 11 types of 1a, 1b, 1c, 2a, 2b, 2c, 3a, 3b, 4a, 5a and 6a based on mutations in the NS-5 region of HCV. . In the future, HCV genotypes are expected to be based on this classification. Therefore, in order to efficiently use various information related to HCV that will be provided in the future, it is necessary to classify HCV genotypes based on the international unified classification method.

  Japanese Patent Application Laid-Open No. 5-301887 discloses a method for determining genotype of HCV using PCR. That is, sequences specific to each genotype are selected, oligonucleotides that hybridize to these sequences are used as primers, PCR is performed using the cDNA of the HCV genome in the test sample as a template, and DNA is amplified by the PCR. A method is described for classifying HCV genotypes by measuring whether or not they are further, and further measuring the size of the amplified DNA.

Japanese National Patent Publication No. 5-500155 Japanese Patent Laid-Open No. 5-301887 Hepatology, 19: 1321-1334, 1994, Correspondence, "A Proposed System for the Nomenclature of Hepatitis C Viral Genotypes"

  However, in this method, the genotype classification is unique and not based on the international unified classification method. Therefore, classification based on the international unified classification method cannot be performed by using the primers described in this publication. In addition, as shown in the Examples below, this method frequently occurs that HCV is determined to be negative for some types even though HCV is present in the sample. Therefore, there is a need for a means for accurately classifying HCV genotypes based on the international unified classification method.

  Accordingly, an object of the present invention is to provide a means for accurately and conveniently classifying HCV genotypes based on the international unified classification method.

As a result of intensive studies using a large number of test samples, the present inventors have been able to classify HCV genotypes based on the internationally unified classification method without duplication, and primers that can efficiently amplify by PCR The present invention was completed by successfully setting the area .

That is, the present invention relates to a step of synthesizing cDNA using a hepatitis C virus genome in a sample or a part thereof as a template, and using the cDNA as a template, from the nucleotide sequences set forth in SEQ ID NOs: 17, 66 and 35 in the sequence listing. PCR and containing rows Ukoto provides method for discriminating genotypes 1a of hepatitis C virus by using the composed oligonucleotide simultaneously as primers.

INDUSTRIAL APPLICABILITY According to the present invention, a novel oligonucleotide that can be used to accurately and conveniently classify HCV genotypes based on the international unified classification method, a primer comprising the same, and a method for distinguishing HCV genotypes using the same Was provided .

  The inventors of the present application added 6b (7a), 6c (7b), 6d (8a), and 6g in addition to the classification based on the above-mentioned international unified classification method (GenBank Accession No. D64170 and D64173). Among these, the present invention also provides a primer that enables the determination of 6b. In 6b, VN787 (GenBank Accession No. D17486), VN843 (GenBank Accession No. D17489), VN540 (GenBank Accession No. D14209), B5 and B7 strains (GenBank Accession No. D64170 and D64173).

As described above, oligonucleotides that can be used in the method of the present invention are those represented by SEQ ID NOs: 1 to 30, 47, 48, and 66 to 69 in the Sequence Listing. When these oligonucleotides are used as primers, the region on the HCV genome to which each primer hybridizes, the type of the sense strand or antisense strand of the region, the type that can be discriminated by the primer, and the inventors of this application for convenience The attached primer names are shown in Table 1 below.

＊：「センス又はアンチセンス」の表示は、プライマーがハイブリダイズするＤＮＡ鎖がセンス鎖かアンチセンス鎖かを示す。

*: “Sense or antisense” indicates whether the DNA strand to which the primer hybridizes is a sense strand or an antisense strand.

  In Table 1, “Consensus” is a primer that hybridizes in common to all types. In SEQ ID NO: 2, “N” represents A, T, G, C or I (inosine).

  In addition, Table 2 below shows the HCV strain name that serves as a reference for the base number of the region on the genome of each genotype in Table 1 and the base number.

＊：１ａのうち、配列番号２５〜２８
文献１：Ohno, T. et al., Thesis (1993) The University of Tokyo, "Hepatitis C Virus"
文献２：Wu Rong-Rong et al, Journal of Medical Virology (1994, in press)
文献３：Ohno Tomoyoshi et al., Journal of Gastroenterology (1994, in press)
文献４：Ohno Tomoyoshi et al., Journal of Medical Virology 42: 409-413 (1994)
文献５：Bukh et al., Proc. Natl. Acad. Sci. U.S.A. 91, 8239-8243 (1994)
文献６：Choo, Q.-L., et al, "Genetic organization and diversity of the hepatitis C virus" Proc. Natl. Acad. Sci. U.S.A. 88, 2451-2455 (1991)

* SEQ ID NO: 25-28 of 1a
Reference 1: Ohno, T. et al., Thesis (1993) The University of Tokyo, "Hepatitis C Virus"
Reference 2: Wu Rong-Rong et al, Journal of Medical Virology (1994, in press)
Reference 3: Ohno Tomoyoshi et al., Journal of Gastroenterology (1994, in press)
Reference 4: Ohno Tomoyoshi et al., Journal of Medical Virology 42: 409-413 (1994)
Reference 5: Bukh et al., Proc. Natl. Acad. Sci. USA 91, 8239-8243 (1994)
Reference 6: Choo, Q.-L., et al, "Genetic organization and diversity of the hepatitis C virus" Proc. Natl. Acad. Sci. USA 88, 2451-2455 (1991)

  Since what is amplified by PCR, which will be described later, is double-stranded cDNA, the same region is amplified even if a combination of oligonucleotides each having a sequence complementary to each of the above oligonucleotides is used as a primer. Therefore, these complementary oligonucleotides can also be used as primers for genotype discrimination of HCV and fall within the scope of the present invention.

  Each of the above oligonucleotides can be easily prepared by chemical synthesis using a commercially available DNA synthesizer.

  In order to classify the genotype of HCV in a specimen by the method of the present invention, first, cDNA complementary to the HCV RNA in the specimen is prepared. cDNA can be prepared using reverse transcriptase and a primer, and this method itself is well known, and an example thereof is described in the following examples.

  Subsequently, PCR is performed using the obtained cDNA as a template and the oligonucleotide of the present invention as a primer. The PCR method itself is well known in this field (Saiki et al., Science, 239, 487-491, 1988). These primers are used with primers that hybridize to the sense strand and primers that hybridize to the antisense strand. In the presence of the primer, template DNA, and heat-resistant DNA polymerase, the cycle comprising annealing, extension, and denaturation steps can be repeated 20 to 40 times. An example of PCR is also described in the examples below.

  PCR always requires at least a pair of primers, which must hybridize to the sense strand and the antisense strand of the template DNA, respectively. Accordingly, a primer (see Table 1) for the type to be discriminated is selected, and a primer (consensus primer or a primer for that type) that hybridizes to the opposite strand is selected to perform the PCR. Since a primer for discriminating a specific type hybridizes only to the template DNA of that type and cannot hybridize to other types of template DNA, if amplification occurs even if the primer is used, the HCV in the sample Is a genotype of that type.

  However, if genotype discrimination is performed using one pair of primers, it is inconvenient because PCR must be performed many times for one specimen. If PCR is performed using three or more types of primers at the same time and regions of different sizes are amplified depending on the genotype, it is advantageous because a plurality of genotypes can be distinguished by a single PCR. It is. The primer of the present invention is selected as such, and when PCR is performed using a mixture of these, a region having a different size is amplified depending on each genotype.

  However, when PCR is performed with all the primers of the present invention mixed, the number of bands to be detected in the subsequent electrophoresis step becomes too large, and it is necessary to identify and detect nearby bands. Is no longer easy. However, if electrophoresis is performed using a sufficiently large gel over a long period of time, even bands of close sizes can be detected at distant positions, so that all primers can be mixed and used.

  As described above, since it is inconvenient to mix and use all the primers, it is preferable to use three or more primers as a set. In this case, each primer set preferably includes a pair of consensus primers (sense and antisense). If a pair of consensus primers is included, if HCV is present in the sample, an amplification band is always used regardless of the genotype (hereinafter, a band amplified by a pair of consensus primers may be referred to as a consensus band). If no band is detected by each genotype-specific primer, is the sample negative for HCV or is it not detectable with the primer used for the type of HCV contained in the sample? It is preferable because it can be known. Furthermore, a plurality of primers for detecting one genotype can be included in each primer set. In this way, even if one primer fails to amplify, if replication occurs successfully with other primers that detect the same genotype, that genotype can be detected, thus increasing the certainty of determination. be able to.

  The inventors of the present application have taken into account such points and succeeded in setting a very preferable primer combination for actual analysis of the specimen. They are shown in Tables 3-17 below. However, the combination of primers is not limited to the following specific examples, and in short, it is sufficient that sense and antisense primers for amplifying each genotype are included.

(1) Primer set 1 (for type discrimination of 1b, 2a, 2b, 3b)

(2) Primer set 2 (for type discrimination of 1a, 3a, 4a, 5a, 6a)

(3) Primer set 3 (for type discrimination of 1b, 2a, 2b)

(4) Primer set 4 (for type discrimination of 1a)

(5) Primer set 5 (1a, 1b, 2a, 2b type discrimination)

(6) Primer set 6 (for type discrimination of 1a and 1b)

(7) Primer set 7 (for type discrimination of 1b, 2a, 2b)

(8) Primer set 8 (for type discrimination of 1b, 2a, 2b, 3b)

（なお、ＯＭＭ３ｂはＯＭＭ１５の配列を限定したもので、その塩基配列は配列表の配列番号４２に示されている）。

(Note that OMM3b has a limited sequence of OMM15, and its base sequence is shown in SEQ ID NO: 42 in the sequence listing).

(9) Primer set 9 (for type discrimination of 1a, 3a, 4a, 5a)

（なお、ＯＭＭ１ａＳ、ＯＭＭ１ａＡ、ＯＭＭ３ａ、ＯＭＭ４ａ及びＯＭＭ５ａは、それぞれＯＭＭ２１、ＯＭＭ２１１、ＯＭＭ２３、ＯＭＭ２４及びＯＭＭ２５の塩基配列を限定したもので、その塩基配列は配列表の配列番号４５、４６、４１、４３及び４４にそれぞれ示されている。）

(Note that OMM1aS, OMM1aA, OMM3a, OMM4a, and OMM5a are limited to the base sequences of OMM21, OMM211, OMM23, OMM24, and OMM25, respectively. 44, respectively.)

(10) Primer set 10 (for type discrimination of 1a, 3a, 4a, 5a, 6a)

(11) Primer set 11 (for type discrimination of 1a, 3a, 4a, 5a, 6a)

（なお、ＯＭＭ２１ＴＣＳは、ＯＭＭ２１ＴＣの塩基配列を限定したもので、その塩基配列は配列表の配列番号４９に示されている）。

(Note that OMM21TCS limits the base sequence of OMM21TC, and the base sequence is shown in SEQ ID NO: 49 in the sequence listing).

(12) Primer set 12 (for type discrimination of 1b, 2a, 2b)

（なお、ＯＭＭ１ｂ、ＯＭＭ２ａＳ、ＯＭＭ２ａＡ及びＯＭＭ２ｂは、それぞれＯＭＭ１１、ＯＭＭ１２１、ＯＭＭ１３及びＯＭＭ１４の塩基配列を限定したもので、その塩基配列は配列表の配列番号６２、６３、６４及び６５にそれぞれ示されている）。

(Note that OMM1b, OMM2aS, OMM2aA, and OMM2b are limited to the base sequences of OMM11, OMM121, OMM13, and OMM14, respectively. )

(13) Primer set 13 (for type discrimination of 1a)

（なお、ＯＭＭ２２Ｃは、ＯＭＭ２２の塩基配列を限定したもので、その塩基配列は配列表の配列番号３５に示されている）。

(Note that OMM22C has a limited base sequence of OMM22, and the base sequence is shown in SEQ ID NO: 35 in the sequence listing).

(14) Primer set 14 (for type discrimination of 3a, 4a, 5a)

(15) Primer set 15 (for type discrimination of 3b, 6a, 6b)

  As apparent from the above, when each primer set is used alone, only the genotypes described at the beginning of each table can be detected. However, it is possible to discriminate more genotypes by performing PCR on each specimen using a plurality of the above primer sets separately. For example, by performing PCR using the primer sets 1 and 2 separately, the genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4a, 5a and 6a can be distinguished.

  As described in the Examples below, FIGS. 1 to 15 show electrophoresis patterns when PCR is performed using each of the above primer sets.

  Subsequently, the amplification product amplified by PCR is detected. The amplification product is preferably detected by gel electrophoresis. Methods for separating and detecting DNA by gel electrophoresis are well known in this field, and an example is described in the following examples.

  Prior to amplification using a genotype-specific primer, amplification was performed by PCR using a pair of consensus primers, and then PCR was performed using a genotype-specific primer (for example, the above primer set), whereby analysis was performed. Sensitivity can be further increased. A preferred primer includes a combination of OMM1 and OMM2.

  The oligonucleotide of the present invention can be used not only as a primer but also as a probe for HCV genotype discrimination by attaching an appropriate label. In this case, it may be extended from each of the above oligonucleotides, and in particular, it may be extended by several bases in the 3 'terminal direction.

  Some regions of the HCV genome to which the oligonucleotides of the present invention hybridize encode peptides having amino acid sequences specific for each genotype. Therefore, by reacting an antibody that specifically reacts with the amino acid sequence with HCV, the type of HCV contained in the specimen can be directly determined. In addition, by reacting peptides containing these amino acid sequences with body fluids such as serum, antibodies specific to each HCV genotype contained in the body fluid can be detected, whereby HCV type discrimination It can be performed. These can be easily performed by well-known immunoassay such as sandwich ELISA, radioimmunoassay, latex agglutination method and the like.

  The amino acid sequences specific to each genotype encoded by the HCV genome in the region to which the oligonucleotide of the present invention hybridizes are shown in SEQ ID NOs: 50 to 61 in the sequence listing. The name of each oligonucleotide and the amino acid sequence HCV genotypes specific to the amino acid sequence (shown by SEQ ID NO) are shown in Table 18 below.

  Hereinafter, the present invention will be described more specifically based on examples. However, the present invention is not limited to the following examples. In addition, as for the primer used in the following example, when a symbol indicating a plurality of bases is used in the sequence described in the sequence table indicating the primer, a mixture of bases indicated by those symbols is used. It was.

Example 1
(1) Sample preparation 100 μl of HCV carrier serum (213 samples) was mixed with 900 μl of RNAzolB (trade name, biotex inc., USA) and 150 μl of chloroform, stirred for 5 seconds, and incubated at −20 ° C. for 5 minutes. The mixture was then centrifuged at 12000 rpm for 5 minutes, and the supernatant was mixed with 500 μl of isopropanol and 20 μg of glycogen and incubated at −20 ° C. for 15 minutes. This was then centrifuged at 12000 rpm for 20 minutes. 1 ml of 75% ethanol was added to the precipitate, suspended, and centrifuged at 12000 rpm for 3 minutes. This 75% ethanol treatment-centrifugation operation was further performed twice, and the precipitate was dried in a desiccator for 15 minutes to obtain purified RNA.

(2) Preparation of Primer Oligonucleotide (primer) was synthesized by Model 394 DNA synthesizer (trade name, Perkin-Elmer Corporation) or 8909 expedite (TM) Nucleic Acid synthesis system (trade name, Millipore Corporation). Furthermore, it refine | purified by the conventional method using OPC column or HPLC.

(3) cDNA synthesis For cDNA synthesis, diethylpyrocarbonate was added to 0.2% of purified and dried RNA in water purified with 15 μl of DEPC-treated water (Milli-Q reagent water system (Millipore), After stirring for 16 hours and further dissolving in high-temperature high-pressure sterilization (autoclave-treated water), heating at 60 ° C. for 5 minutes, 100 units of Moloney murine virus reverse transcriptase (trade name; GIBCO- 15 μl of reverse transcription solution (50 mM Tris-HCl (pH 8.3), 75 mM KCl, 3 mM MgCl ₂ , 10 mM dithiothreitol) containing BRL, USA) was added and heated at 42 ° C. for 60 minutes. In addition, 10 pmol of OMM2 was used as a primer for cDNA synthesis.

(4) PCR
In order to increase the detection sensitivity, in the first PCR, the cDNA was PCR amplified using the consensus primers OMM1 and OMM2 (Saiki et al., Science 239, 481-491, 1988). The reaction solution was 10 mM Tris-HCl (pH 8.3), 1.5 mM MgCl ₂ , 50 mM KCl, 800 μM dNTP, 1.25 units of AmpliTaq DNA polymerase (trade name, Japan ROCHE), primers OMM1 and OMM2 at 5 pmol each. . PCR conditions were as follows: cycle 35, denaturation 94 ° C., 30 seconds, annealing 50 ° C., 30 seconds, extension 72 ° C., 1 minute. Further, the amplification product was subjected to second PCR amplification (PCR cycle 25, denaturation 94 ° C., 30 seconds, annealing 62 ° C., 30 seconds, extension 72 ° C., 1 minute) with the above primer sets 1, 2, 3, or 4 respectively. .

(5) Electrophoresis The obtained amplification product was electrophoresed (150 V constant current) on an agarose gel (Tris-borate buffer, 0.5 μg / ml ethidium bromide). After electrophoresis, polaroid (polaroid type 667) was photographed under ultraviolet irradiation. The type was determined based on the difference in band mobility.

(6) Results FIGS. 1, 2, 3, and 4 show the electrophoresis patterns obtained using the primer sets 1, 2, 3, and 4, respectively. In each figure, the leftmost lane shows the migration pattern of molecular weight markers. In each lane, a consensus band is a band of an amplification product amplified by a consensus primer included in each primer set. If HCV is present in a sample, it is always at a fixed position regardless of its genotype. It is what appears. The right side of the band specific to each genotype is shown with a short arrow. If the band indicated by this arrow is detected, the HCV genotype of the sample is the genotype of the type described at the top of the lane where the band is located. As is clear from each figure, it was confirmed that by using the primer of the present invention, HCV genotypes can be classified according to the internationally unified classification.

Example 2
Random hexamer oligonucleotides are used as primers for cDNA amplification, OMM1, OMM2 and OMM3 are used as primers for the first PCR, primer set 5 is used for the second PCR, and the primer concentration is 10 pmol. Except that, the same procedure as in Example 1 was performed. The obtained electrophoresis pattern is shown in FIG.

Comparative Example 1
The above 213 specimens were subjected to type discrimination by the method described in JP-A-5-301887. As a result, amplification did not occur (HCV negative) for any of the 22 samples (2a type, 20 cases, 2b type, 2 cases) that could be type-determined according to the examples of the present invention. All of the above 213 specimens were positive for HCV by PCR using primers YCS, YCS2 and MS13 set in the 5 ′ untranslated region (described in paragraph 40 of Japanese Patent Application No. 6-142564). This is an HCV positive sample confirmed three times for the sample.

Examples 3 and 4
RNA was extracted in the same manner as in Example 1 from 5 sera of each of the HCV strains 1a, 1b, 2a, and 2b whose base sequences were determined, and OMM2 having the base sequence represented by SEQ ID NO: 31 was used. CDNA synthesis was performed in the same manner as in Example 1.

  Next, using OMM2 having the sequence represented by SEQ ID NO: 31 and OMM1 having the base sequence represented by SEQ ID NO: 32 as primers, the first PCR was performed at 94 ° C. for 30 seconds, 50 ° C. 35 cycles of 30 seconds, 72 ° C., 60 seconds. One-fifth (1 μl) was further amplified by PCR. This second PCR was performed using the primer set 6 (Example 3) or the primer set 7 (Example 4). However, in each primer set, OMM21, OMM211, OMM22, OMM11, OMM12, OMM13, and OMM14 having base sequences represented by SEQ ID NOs: 33, 34, 35, 36, 37, 38, and 39, respectively, were used. . The second PCR was performed for 25 cycles at 94 ° C., 30 seconds, 62 ° C., 30 seconds, 72 ° C., 60 seconds. PCR products were separated by agarose electrophoresis as in Example 1. The obtained electrophoresis patterns are shown in FIGS. 6 and 7, respectively.

Examples 5-8
Except for performing PCR for the second time using primer set 8 (Example 5), primer set 9 (Example 6), primer set 10 (Example 7) or primer set 11 (Example 8). The same operation as in Examples 3 and 4 was performed. The obtained electrophoresis patterns are shown in FIGS. 8, 9, 10 and 11, respectively.

Examples 9-12
Serum derived from 200 patients with chronic hepatitis C was used. RNA was prepared from 150 μl of serum with RNAzol B (trade name; BioLab). For cDNA synthesis, 300 ng of random hexamer (trade name; Gibco BRL), 100 U of MMLV-RT (trade name; Gibco BRL), 50 U of RNase inhibitor (trade name; Takara Shuzo) were used in a 30 μl system for 1 hour. Incubated at 37 ° C. PCR was carried out at 94 ° C., 20 seconds, 50 ° C., 20 seconds, 72 ° C., 45 seconds, 35 times in a 50 μl system using 10 μl of cDNA using 100 ng of each of the above 1st-PCR primers OMM1, 2, and 3. 2 μl of the 1 μl was subjected to 2nd-PCR using each of the type-discriminating primer sets 12 (Example 9), 13 (Example 10), 14 (Example 11), and 15 (Example 12). The conditions are 94 ° C., 20 seconds, 62 ° C., 20 seconds, 72 ° C., 45 seconds, 25 times, and the amplified band is subjected to electrophoresis with 3% agarose (including 0.5% EtBr) (150 V, 30 minutes), DNA size marker, φX174 / The genotype was determined by comparison with the band detected by HaeIII digest (trade name; Toyobo). The obtained electrophoresis patterns are shown in FIGS. 12, 13, 14 and 15, respectively.

Example 13
HCV typing was performed using sera from chronic hepatitis C patients from 11 countries. Specifically, this inspection was performed as follows.

  (1) Sample preparation and the like were carried out in the same manner as in Example 1. For cDNA synthesis, primers OMM1, OMM2, OMM3 and random hexamers (trade name: Gibco BRL) were used.

(2) PCR
In order to increase detection sensitivity, in the first PCR, the cDNA was PCR amplified using consensus primers OMM1, OMM2, and OMM3. Furthermore, the amplification products were subjected to PCR amplification (PCR cycle 25, denaturation 94 ° C., 15 seconds, annealing 62 ° C., 15 seconds, extension 72 ° C., respectively) with the primer sets A, B, C and D shown in Tables 19 to 22 below. 45 seconds).

Primer set 1) Primer set A (for type discrimination of 1b, 2a, 2b)

  2) Primer set B (for type discrimination of 1a)

  3) Primer set C (3a, 5a, 4 type discrimination)

  4) Primer set D (for type discrimination of 3b, 6a, 6b)

(3) Electrophoresis The obtained amplification product was subjected to electrophoresis (150 V constant current) with a 3% agarose gel (Tris-borate buffer, 0.5 μg / ml ethidium bromide). After electrophoresis, polaroid (polaroid type 667) was photographed under ultraviolet irradiation. The type was determined based on the difference in band mobility.

  In the above method, the electrophoresis patterns obtained for each of the primer sets A, B, C, and D are shown in FIGS. In addition, Table 23 below shows the number of people having the type determined by the above method, by region.

＊：パキスタン／バングラデシュ

*: Pakistan / Bangladesh

It is a schematic diagram of the electrophoresis pattern obtained by performing PCR using the primer set 1. It is a schematic diagram of the electrophoresis pattern obtained by performing PCR using the primer set 2. It is a schematic diagram of the electrophoresis pattern obtained by performing PCR using the primer set 3. It is a schematic diagram of the electrophoresis pattern obtained by performing PCR using the primer set 4. 6 is a schematic diagram of an electrophoresis pattern obtained by performing PCR using primer set 5. FIG. 6 is a schematic diagram of an electrophoresis pattern obtained by performing PCR using primer set 6. FIG. It is a schematic diagram of the electrophoresis pattern obtained by performing PCR using the primer set 7. It is a schematic diagram of the electrophoresis pattern obtained by performing PCR using the primer set 8. It is a schematic diagram of the electrophoresis pattern obtained by performing PCR using the primer set 9. 2 is a schematic diagram of an electrophoresis pattern obtained by performing PCR using the primer set 10. FIG. It is a schematic diagram of the electrophoresis pattern obtained by performing PCR using the primer set 11. It is a schematic diagram of the electrophoresis pattern obtained by performing PCR using the primer set 12. It is a schematic diagram of the electrophoresis pattern obtained by performing PCR using the primer set 13. It is a schematic diagram of the electrophoresis pattern obtained by performing PCR using the primer set. It is a schematic diagram of the electrophoresis pattern obtained by performing PCR using the primer set 15. It is a schematic diagram of the electrophoresis pattern obtained by performing PCR using the primer set A. It is a schematic diagram of the electrophoresis pattern obtained by performing PCR using the primer set B. It is a schematic diagram of the electrophoresis pattern obtained by performing PCR using the primer set C. It is a schematic diagram of the electrophoresis pattern obtained by performing PCR using the primer set D.

Claims (1)

A step of synthesizing cDNA using a hepatitis C virus genome in a sample or a part thereof as a template, and an oligonucleotide comprising the nucleotide sequences set forth in SEQ ID NOs: 17, 66 and 35 of the sequence listing as primers. A method for discriminating genotype 1a of hepatitis C virus, comprising performing PCR using

Images